Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 7/20 | 0.57 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15448880 | 1.00 | TK1 (0.57) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL19928644 | 0.89 | TK1 (0.57) | TK1RNASE1 | |
| SCHEMBL13304396 | 0.88 | LMNA (0.56) | TK1RNASE1LMNAPMP22 | |
| SCHEMBL12015131 | 0.85 | TK1 (0.60) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL26189529 | 0.85 | TK1 (0.60) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL12087585 | 0.85 | TK1 (0.60) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL23102036 | 0.84 | TK1 (0.56) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL15498298 | 0.83 | RNASE1 (0.63) | TK1RNASE1 | |
| SCHEMBL22855496 | 0.83 | TK1 (0.61) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL19884474 | 0.83 | TK1 (0.61) | TK1RNASE1ALBPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8710210-B2 | Method of using N-thio compounds for oligonucleotide synthesis | GIRINDUS AMERICA, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130096291-A1 | New Method of Using N-Thio Compounds for Oligonucleotide Synthesis | GIRINDUS AMERICA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096291-A1 | New Method of Using N-Thio Compounds for Oligonucleotide Synthesis | RNGTT, TST, NOP2 | TK1 43/4885RNASE1 369/4885ALB 2785/4885 |
| US-20140179875-A1 | SULFURIZATION REAGENTS ON SOLID SUPPORTS | OR10J3, RPS8, NSUN2 | TK1 2907/4885RNASE1 2182/4885ALB 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.